Ratings Allogene Therapeutics, Inc.

Equities

ALLO

US0197701065

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
3.01 ^USD	-1.95%		+5.99%	-6.23%

Apr. 26	Allogene Therapeutics Gets $15 Million Grant from California Institute for Regenerative Medicine for Cancer Drug Development	MT
Apr. 26	Allogene Therapeutics Receives Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
Based on current prices, the company has particularly high valuation levels.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
ALLOGENE THERAPEUTICS, INC.	-6.23%	524M	B-
REGENERON PHARMACEUTICALS, INC.	+9.15%	105B	B+
VERTEX PHARMACEUTICALS INCORPORATED	-1.08%	104B	B+
ARGENX SE	+5.79%	22.94B	B
BIONTECH SE	-11.55%	22.34B	B+
GENMAB A/S	-7.01%	19.25B	A-
WUXI APPTEC CO., LTD.	-37.08%	17.08B	A-
BEIGENE, LTD.	-9.91%	16.96B	B
NEUROCRINE BIOSCIENCES, INC.	+7.55%	14.16B	C+
SAREPTA THERAPEUTICS, INC.	+40.04%	12.63B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes